Irish firm raises $20m for heart disease drug trials

An Irish biotechnology company developing drugs to tackle a heart disease that causes sudden death in young athletes has raised $20m (€14.5m) Series A financing for clinical drug trials.

Heart Metabolics Limited has developed a drug, perhexiline, which has already completed phase two clinical trials as a treatment for hypertrophic cardiomyopathy.

Heart Metabolics CEO Peter Milner said he was confident that they have an effective therapy for the fatal heart disease.